7 Best Peptides for Liver Detox

What to Know Before Choosing a Peptide for Liver Detox

The phrase "liver detox" covers a wide range of goals: reducing fat accumulation in the liver, protecting liver cells from oxidative damage, slowing the progression of fibrosis, and supporting the natural enzyme pathways that clear toxins and metabolic waste. No single peptide does all of these things, and none of them directly flushes toxins in the way that phrase is sometimes marketed. What these compounds do is address the conditions that impair liver function, such as oxidative stress, inflammation, fat accumulation, and scarring, so the liver's own detoxification systems can work more efficiently.

A compound earns a slot on this list because people use it, or are actively discussing using it, for liver detox and liver health. That is the whole test. FDA-approved medications, telemedicine-prescribed compounds, and research-only peptides are all eligible. So are compounds with community-reported use and limited formal study. Where the evidence is thin, this guide says so plainly rather than quietly leaving a widely-discussed compound off the list. The strength of the evidence shapes how each entry is written, never whether the compound appears at all.

The entries below are numbered by how prominently each compound appears in research and documented real-world use for liver detox, not as a ranking of one being better than another for you. The field ranges from FDA-approved therapies with Phase 3 human trial data to research-only peptides with no published human trials to bioregulators with a user-reported experience base and limited formal study. Understanding where each one sits is the whole point of the list.

1. Semaglutide: The Most Clinically Validated Option

Semaglutide is a GLP-1 receptor agonist, a peptide that mimics a gut hormone called glucagon-like peptide-1, which signals the liver and other tissues to reduce fat storage and increase fat burning. It is FDA-approved for type 2 diabetes and obesity under the brand names Ozempic and Wegovy, and it received accelerated FDA approval for non-cirrhotic metabolic-associated steatohepatitis in 2025, making it the most formally recognized peptide therapy for a specific liver disease currently available.

The human evidence behind semaglutide for liver health is the strongest of any compound in the liver detox conversation. In a Phase 2 randomized controlled trial published in the New England Journal of Medicine, 59 percent of participants receiving semaglutide showed NASH resolution without worsening fibrosis, compared with 17 percent in the placebo group. Real-world clinical data consistently show reductions in ALT and AST, the standard liver enzyme markers of cellular stress, along with measurable reductions in liver fat on imaging.

The mechanism is direct. Semaglutide binds to GLP-1 receptors on liver cells and in the gut, reducing the liver's production of new fat from carbohydrates, increasing fat oxidation, and dampening the inflammatory signals that drive fatty liver toward scarring. The weight-loss effect provides an additional layer of benefit: lower overall fat burden means less fat accumulating in the liver over time.

Semaglutide is a prescription medication obtained through a physician or a telemedicine platform. It is not a research chemical, and its path to access is clearer than any other compound on this list. For anyone whose liver concern is rooted in metabolic liver disease, fatty liver, or NASH, this is where the human evidence base is deepest.

2. Tirzepatide: The Dual-Agonist With Striking Fat Reduction Data

Tirzepatide targets two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). That dual action gives it a broader effect on fat metabolism and insulin signaling than a single GLP-1 agonist alone. It is FDA-approved for type 2 diabetes and obesity under the brand names Mounjaro and Zepbound, and it is widely used off-label for metabolic liver disease while its formal MASH approval works through the regulatory process.

The human trial data for tirzepatide and liver health are striking. Phase 2 and Phase 3 trials have shown fibrosis improvement rates in the range of 54 to 59 percent, and reductions in liver fat by as much as 8 percent in controlled studies. Community accounts align closely with the clinical picture. Users in liver health communities have shared FibroScan results showing progression from Stage 3 fatty liver to Stage 0 within roughly one year of use, and accounts of dramatic metabolic improvement appear regularly in peptide and biohacking forums.

Tirzepatide's liver benefit flows through multiple pathways: reducing de novo lipogenesis (the liver's own creation of new fat from sugar and carbohydrates), increasing fat oxidation through mitochondrial pathways, and reducing the inflammatory signaling that moves steatosis toward hepatitis and eventually scarring. The dual-receptor mechanism may explain why fat-reduction numbers in trials tend to run higher than those seen with GLP-1 agonists alone.

Like semaglutide, tirzepatide is a prescription medication. Access is through a physician or a telemedicine platform, and dose escalation is managed under medical supervision.

3. BPC-157: The Research Peptide With the Broadest Preclinical Evidence

BPC-157 is a synthetic peptide derived from a protein found in gastric juice, and it is among the most actively discussed research peptides in liver health and gut-liver axis conversations. It has more than 30 years of animal research behind it for hepatic applications, including studies showing reductions in liver fat accumulation, lower markers of liver inflammation, inhibition of fibrosis signaling, and protection of liver cells from toxic injury in rodent models.

What BPC-157 does not have, as of 2026, is a single published human clinical trial for liver detox or fatty liver. The animal research is extensive, but the gap to human data is real and should be stated plainly. The FDA has classified BPC-157 as a Category 2 bulk drug substance, citing safety concerns and insufficient human data, which means it is not legal for use in US compounding pharmacies. It is available through research chemical suppliers.

Despite that regulatory status, BPC-157 is one of the most frequently mentioned compounds in community liver protocols. People use it orally for what they describe as gut-liver axis support: healing the intestinal lining to reduce the passage of bacterial endotoxins from the gut into the portal vein, which in turn reduces the inflammatory burden on liver cells. It also appears in community stacks alongside other research compounds for broader hepatic support.

The biological rationale involves upregulation of heme oxygenase-1 and glutathione, inhibition of TGF-beta (the primary driver of fibrosis signaling), and nitric oxide modulation to improve blood flow through liver tissue. Whether those preclinical mechanisms translate to meaningful benefit in humans is genuinely unknown. Anyone using BPC-157 in 2026 is working from animal data and community-reported experience, not a clinical evidence base.

4. Glutathione: The Liver's Primary Internal Detoxifier

Glutathione is a tripeptide: three amino acids, glycine, cysteine, and glutamic acid, linked together by the body into the most abundant intracellular antioxidant in human physiology. It is not a synthetic research peptide and not a pharmaceutical. It is a molecule the body produces continuously, concentrated most heavily in the liver, where it serves as the central cofactor in Phase II detoxification: the process by which the liver attaches glutathione to toxic compounds and metabolic waste to make them water-soluble and ready for excretion.

When liver cells are under oxidative stress, from alcohol, medications, metabolic disease, or toxin exposure, glutathione levels drop. A liver running low on glutathione has reduced capacity to process toxins through Phase II pathways. That is the straightforward reason glutathione appears in any serious discussion of liver detox: it is the molecule the liver most depends on to do the work that "detox" is describing.

In clinical and wellness settings, glutathione is administered by IV or injection for liver support. Users in community protocols report using injectable glutathione for what they describe as liver detox and immune support. Oral glutathione has historically poor bioavailability because stomach acid degrades it before absorption, which is why liposomal oral formulations and N-acetylcysteine (NAC), a direct precursor to glutathione with better oral absorption, are often preferred in practice.

NAC has Phase 3 clinical trial data supporting its use as a liver protectant, most notably its established medical role in treating acetaminophen overdose-induced liver toxicity. Among all the compounds discussed here, glutathione and NAC occupy a unique position: the most mechanistically central to liver detoxification, with established human safety profiles, while sitting outside the research-peptide category most users are searching within.

5. SS-31: Mitochondrial Protection for Liver Cells

SS-31, also known as elamipretide, is a synthetic tetrapeptide that targets the inner membrane of mitochondria, the energy-producing structures inside cells. Its relevance to liver health comes from a specific mechanism: protecting cardiolipin, a phospholipid critical to the structure and function of the inner mitochondrial membrane, from oxidative damage. Think of cardiolipin as the scaffolding that keeps the mitochondria's internal assembly line running. When it degrades, the whole energy production process breaks down, and the cell becomes vulnerable to death.

In liver cells under oxidative stress, from alcohol, metabolic disease, or toxin exposure, this is often how hepatocytes are lost. SS-31 reduces the production of reactive oxygen species at the mitochondrial level, preserves the structural integrity of the inner membrane under oxidative stress, and reduces the rate of liver cell death in animal models of liver injury.

The evidence for SS-31 in liver applications is preclinical. No published human clinical trial has examined it specifically for liver disease or liver detox as of 2026. Its early clinical investigation has occurred in cardiovascular and renal contexts, not hepatic ones. The case for it in liver protocols rests on animal studies and the strength of its mechanistic rationale in a well-validated biological pathway.

In community protocols, SS-31 appears most often as a companion compound to oral BPC-157, particularly in stacks targeting NAFLD and alcohol-related liver inflammation. Whether that combination produces meaningful benefit in humans is not established by controlled research. SS-31 is a research-grade compound, not FDA-approved for any indication as of 2026.

6. Svetinorm: The Liver-Targeting Bioregulator

Svetinorm is a short-chain peptide bioregulator in the tradition of organ-targeting peptides developed primarily within Eastern European research programs over several decades. Bioregulator peptides are short amino acid sequences, typically two to four amino acids long, designed to act on specific tissues and support their normal physiological function. Svetinorm is identified within this research tradition as specifically targeting the liver.

The evidence base for Svetinorm is different in character from anything else on this list. It does not appear in large-scale English-language randomized controlled trials. Its research background is in Eastern European scientific literature, with some preclinical and limited human data that has not been widely replicated or reviewed within Western clinical frameworks. No human clinical trial for Svetinorm in liver detox has been published in major peer-reviewed journals as of 2026.

In community discussion, Svetinorm comes up alongside Ovagen and similar bioregulators as a liver support option. Opinions within peptide and biohacking communities are genuinely divided. Some users report personally meaningful results, describing improvements in energy, digestion, and subjective liver-health markers. Others, particularly users tracking objective outcomes like FibroScan scores, tend to report that GLP-1 agonists and injectable research peptides produce more verifiable improvements. The bioregulators, in that comparison, are described as producing subtler effects that are harder to confirm without objective testing.

Svetinorm is available as a research compound or supplement depending on jurisdiction and is not FDA-approved. Its evidence is grounded in Eastern European research literature and user-reported experience, and that is described honestly here rather than inflated.

7. Ovagen: The Organ-Specific Bioregulator

Ovagen belongs to the same class as Svetinorm: a short-chain peptide bioregulator designed to target specific tissues and support their function. In biohacking and research peptide communities, Ovagen is cited in liver support and liver detox contexts, sometimes alongside Svetinorm, sometimes independently. Like other bioregulators in this tradition, its design premise is organ specificity: the compound is intended to act on hepatic tissue and support liver function at the cellular level.

The evidence situation for Ovagen mirrors Svetinorm: limited English-language clinical trial data, roots in Eastern European bioregulator research, and an evidence base that rests more on that research tradition and community-reported experience than on large-scale human trials recognized by Western regulatory bodies. No major peer-reviewed human trial for Ovagen in liver detox has been published in major English-language journals as of 2026.

Community reports on Ovagen are mixed. Some users in peptide communities report genuinely good personal results from liver bioregulators, describing them as part of a broader supplement and peptide approach. Others express skepticism, noting that without objective measurement tools like liver enzyme panels or imaging, the effects are difficult to distinguish from general wellness improvements. The honest position is that Ovagen has real use and real discussion behind it, with an evidence base that is experiential rather than clinical.

Ovagen is available as a research compound or supplement and is not FDA-approved. It is included here because people use it and discuss it for liver detox, which is the criterion for inclusion on this list. A guide that left it out would be incomplete for the reader who has already encountered it in community discussions. Anyone approaching it should understand clearly that what exists is user-reported experience, not published human trial data.

How These Peptides Compare

Frequently Asked Questions

Are these compounds legal to obtain for liver support?

The answer varies significantly by compound. Semaglutide and tirzepatide are FDA-approved prescription medications obtained legally through a physician or licensed telemedicine platform. Glutathione and its precursor NAC are available as supplements or through clinical infusion services without a prescription in most jurisdictions. BPC-157 and SS-31 are research-grade compounds not approved for human use by the FDA, meaning they are not legal in US compounding pharmacies but are available through research chemical suppliers. Svetinorm and Ovagen fall into a supplement or research compound category depending on the jurisdiction, and neither is FDA-approved.

Can any of these compounds produce measurable improvements in liver markers?

For the GLP-1 agonists, yes: human trial data shows measurable reductions in ALT and AST, reductions in liver fat on imaging, and improvements in fibrosis scores on FibroScan and biopsy in clinical studies. For research peptides like BPC-157 and SS-31, improvements are well-established in animal models, but no controlled human trial has confirmed whether those effects translate to measurable changes in human liver function tests. For bioregulators like Svetinorm and Ovagen, individual users report subjective improvement, but objective published outcome data from peer-reviewed research is not available as of 2026.

Do peptides work the same way as a commercial liver detox cleanse?

No, and the distinction is meaningful. Commercial liver detox cleanses are not supported by clinical evidence and typically work through laxative or diuretic effects rather than any specific change in liver biology. The compounds on this list, where they have evidence, work by addressing specific biological drivers of liver disease: fat accumulation, oxidative stress, inflammation, and cellular energy production. They support the liver's own detoxification pathways by reducing the burden on them, not by flushing anything through a mechanism that commercial detox products generally do not have.

Is it safe to combine multiple compounds from this list?

Community protocols often combine compounds, with oral BPC-157 paired with SS-31 being one commonly cited stack for NAFLD support. Safety data for these combinations in humans is essentially absent, as no clinical trial has examined them together. The GLP-1 agonists are well-studied individually and managed under physician supervision, which provides a safety framework. For research compounds, combining them without medical oversight introduces unknown interaction risks. Anyone considering pairing compounds from this list, particularly research-grade ones, should discuss the approach with a qualified healthcare professional familiar with these agents.

How long before liver health improvements become apparent?

For GLP-1 agonists, clinical trials show meaningful changes in liver fat and enzyme markers over periods of 24 to 72 weeks, with earlier metabolic improvements often appearing before structural liver changes are measurable. For research compounds like BPC-157 and SS-31, community protocols typically run 8 to 12 weeks, though no controlled human data establishes what timeline to expect for liver-specific outcomes. For bioregulators, the user-reported experience is similarly variable and not grounded in controlled research timelines. The timeline depends heavily on which compound is used, the baseline state of liver health, and whether human trial data or only animal and community experience is available to draw from.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for liver detox in one place.